For the first time in the history of cancer: A small cancer trial gave every rectal cancer patient who participated in the trial a complete remission . The study was published in the New England Journal of Medicine. Pharmaceutical giant GlaxoSmithKline sponsored the study in which 18 rectal cancer patients faced difficult treatment options — chemotherapy, radiation, and even life-changing surgery — all of whom believed they would have to undergo surgery after the trial. Unexpectedly, the tumors in their bodies disappeared, undetectable by any test, and they no longer needed any surgery. Medical experts say something like this is unheard of. Another surprise was that none of them observed complications. The trial drug, dostarlimab, is administered every three weeks for six months and costs about $11,000 per dose. It rips off the mask of cancer cells, so the immune system can recognize and destroy them. Harvard colorectal cancer expert Dr. Kimmie Ng said the results need to be replicated.
This article is reprinted from: https://www.solidot.org/story?sid=71768
This site is for inclusion only, and the copyright belongs to the original author.